Dianthus Therapeutics, Inc. Common Stock (DNTH) Stock Price

DNTHStock

$112.11+352.96%52W

Market Cap$6.27B

P/E—

PEG Ratio—

Div yield—

Beta1.86

DNTH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)120.63%

Price vs S&P 500 (4W)5.27%

VGM Score46.85

Book Value / Share (Quarterly)$21.39

P/TBV (Annual)1.61x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.84

Price vs S&P 500 (YTD)155.14%

Net Profit Margin (TTM)-10096.95%

EPS (TTM)$-4.15

10-Day Avg Trading Volume0.66M

EPS Excl Extra (TTM)$-4.15

EPS (Annual)$-4.20

ROI (Annual)-32.90%

Cash / Share (Quarterly)$16.18

Revenue Growth QoQ (YoY)294.30%

ROA (Last FY)-30.58%

Revenue Growth TTM (YoY)-60.77%

EBITD / Share (TTM)$-4.66

ROE (5Y Avg)-39.22%

Operating Margin (TTM)-11441.39%

Cash Flow / Share (Annual)$-2.99

P/B Ratio5.29x

P/B Ratio (Quarterly)4.55x

Net Income / Employee (Annual)$-1,764,500

EV / Revenue (TTM)3195.18x

Net Interest Coverage (TTM)-57.94x

ROA (TTM)-21.55%

EPS Incl Extra (Annual)$-4.20

Current Ratio (Annual)13.32x

Quick Ratio (Quarterly)25.80x

3-Month Avg Trading Volume0.89M

52-Week Price Return352.96%

Revenue / Employee (TTM)$20,700

Tangible BV / Share (Quarterly)$12.04

P/S Ratio (Annual)3042.32x

Asset Turnover (Annual)0.00x

52-Week High$117.88

EPS Excl Extra (Annual)$-4.20

CapEx CAGR (5Y)-11.84%

Tangible BV CAGR (5Y)16.06%

26-Week Price Return131.87%

Quick Ratio (Annual)13.16x

13-Week Price Return22.80%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)26.10x

Enterprise Value$6.08B

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)3.60%

Revenue / Employee (Annual)$22,100

Pretax Margin (Annual)-7973.33%

Cash / Share (Annual)$9.35

3-Month Return Std Dev61.31%

Net Income / Employee (TTM)$-2,089,600

ROE (Last FY)-32.90%

EPS Basic Excl Extra (Annual)$-4.20

Receivables Turnover (TTM)26.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.15

ROI (TTM)-22.53%

P/S Ratio (TTM)3253.24x

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$27.96

Price vs S&P 500 (52W)334.65%

Year-to-Date Return167.10%

5-Day Price Return-4.73%

EPS Normalized (Annual)$-4.20

ROA (5Y Avg)-33.44%

Net Profit Margin (Annual)-7973.33%

Month-to-Date Return2.95%

Cash Flow / Share (TTM)$-14.53

EBITD / Share (Annual)$-4.60

Operating Margin (Annual)-8739.34%

ROI (5Y Avg)-39.22%

EPS Basic Excl Extra (TTM)$-4.15

P/TBV (Quarterly)0.96x

P/B Ratio (Annual)3.58x

Pretax Margin (TTM)-10096.95%

Book Value / Share (Annual)$11.42

Price vs S&P 500 (13W)20.01%

Beta1.86x

Revenue / Share (TTM)$0.03

ROE (TTM)-22.53%

52-Week Low$22.76

vGradeF

gGradeC

mGradeB

vgmGradeC

DNTH Earnings Surprise History

Q2 25-0.88est. -0.87

Q3 25-0.97est. -0.90

Q4 25-1.43est. -1.03

Q1 26-0.85est. -1.10

Q2 26-0.90est. -0.91

DNTH Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.43

4.41

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
DNTHDianthus Therapeutics, Inc. Common Stock	F	C	B	$112.11
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Dianthus Therapeutics, Inc. Common Stock

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation monoclonal antibody therapies targeting complement for severe autoimmune and inflammatory diseases. The company's lead candidate, DNTH103, is a subcutaneous C1s inhibitor designed to offer improved selectivity and potency over existing complement therapies. The team brings substantial biotechnology and pharmaceutical expertise to advance its pipeline.